Coronary Artery Disease
Conditions
Brief summary
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.
Detailed description
REDEEM-CAD is a prospective multi-centre study in which a process of evaluating the risk of coronary artery disease is studied in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago. The efficacy of this CAD risk evaluation will be compared with the broad community in two existing studies - CAUGHT-CAD and EDCAD. This unique Screening/Management Plan (SMP) has 2 components; 1) A novel clinical and imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2) A clinical review to ensure optimal risk factor control and cardio protection. Follow-up of treated patients will continue for an average of 36 months, with clinic reviews at 12, 24 and 36 months. The results will define the prevalence of subclinical coronary artery disease, and the feasibility and the efficacy of the SMP.
Interventions
DIAGNOSTIC_TESTCoronary CT
Screening/Management Plan
Sponsors
Western Health, Australia
Northern Hospital, Australia
Menzies Institute for Medical Research
Peter MacCallum Cancer Centre, Australia
The Alfred
Baker Heart and Diabetes Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
A history of cancer \>5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).
Exclusion criteria
* Unable to provide written informed consent to participate in this study * Known coronary artery disease at recruitment * History of previous coronary artery disease * Inability to acquire interpretable CT images * Contraindications/Intolerance to or already taking statin therapy * Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of evaluated patients who should undergo CAD prevention | 3 years | High clinical risk, or intermediate risk with CAC score \>0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion with critical CAD | 3 years | Coronary stenosis \>70% by CT coronary angiogram |
| Proportion at intermediate clinical risk | 3 years | Intermediate clinical risk (0.8-2.0% annualized risk by Pooled Cohort Equation) |
| Statin responsiveness | 3 year follow-up | Change in plaque volume |
Countries
Australia
Contacts
Primary ContactTom Marwick, MBBS,PhD,MPH
Backup ContactLisa Riddell
Outcome results
None listed